Feature|Articles|September 17, 2024
- Pharmaceutical Executive: September 2024
- Volume 44
- Issue 9
Pharmaceutical Executive: September 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
A Care Sea Changealmost 2 years ago
Jan van de Winkel: Antibody Ascensionalmost 2 years ago
Biotech Performance Pivot May Be in the Offingalmost 2 years ago
Delivery and Disruption: Navigating a Changing Care Terrainalmost 2 years ago
Outsourcing’s Evolution in the Pharma Industryalmost 2 years ago
A Risk-Reward Reset: Getting Serious About Social Mediaalmost 2 years ago
Copay Adjustment Chess Match: What Will Payers Do Next?almost 2 years ago
Rx Power Struggle: How Pharma can Flip the PBM ScriptAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
3
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
4
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
5